Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for BIVV003. Progressed clinical activities in preparation for the third patient. Sangamo Therapeutics stock declined 17% over the last 10 trading days (2 weeks), compared to broader market (S&P500) decline of 2.5%. The process took 3 days. Presented seven posters and one oral presentation at ASGCT on. Consolidated net loss for the second quarter ended June 30, 2022, was $43.2 million, or $0.29 per share, compared to a net loss of $47.2 million, or $0.33 per share, for the same period in 2021. The interview was timely, provided an overview of the company and of the role, asked the candidate to go over their relevant career trajectory and competences. Subscribe to Yahoo Finance Plus to view Fair Value for SGMO. These forward-looking statements include, without limitation, statements relating to: the therapeutic and commercial potential of our product candidates, the anticipated plans and timelines of Sangamo and our collaborators for screening, enrolling and dosing patients in and conducting our ongoing and potential future clinical trials and presenting clinical data from our clinical trials, including expectations regarding presentation of updated clinical data from the Phase 1/2 STAAR study, updates regarding the PRECIZN-1 study, the dosing of patients with product candidates using improved manufacturing methods in the PRECIZN-1 study and the potential impacts thereof, and preparations and plans for dosing the third patient in the STEADFAST study, the anticipated advancement of our product candidates to late-stage development, including potential future Phase 3 trials of isaralgagene civaparvovec and BIVV003, plans and timing regarding the expected resumption of dosing of patients in the Phase 3 AFFINE trial and the availability and presentation of data from such trial, our 2022 financial guidance related to GAAP and non-GAAP total operating expenses and stock-based compensation, and other statements that are not historical fact. The Phase 1/2 STAAR study has transitioned into the expansion phase, with the first five expansion patients dosed at the 5e13 vg/kg dose level, including the first two female patients. Sangamo (SGMO) delivered earnings and revenue surprises of 11.11% and 0.83%, respectively, for the quarter ended December 2022. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP financial information, to more fully understand our business. Analyst Report: Alnylam Pharmaceuticals, Inc. Analyst Report: BioMarin Pharmaceutical Inc. NasdaqGS - NasdaqGS Real Time Price. Each step toward the possibility of eliminating the need for frequent, life-long treatment for the patients and families affected by debilitating disease is exciting. We expect to present additional clinical updates from the STAAR study, including the first data from the expansion cohort, in the first half of 2023. Company is very dedicated to patient engagement as well as inclusion and diversity.Read More. To supplement our financial results and guidance presented in accordance with GAAP, we present non-GAAP total operating expenses, which exclude stock-based compensation expense from GAAP total operating expenses. This is the Sangamo Therapeutics company profile. These decreases were partially offset by a $1.9 million adjustment to revenue during 2021 related to the collaboration agreement with Sanofi and an increase of $0.5 million in revenue related to our collaboration agreement with Kite. Benefits are great. I interviewed at Sangamo Therapeutics (San Francisco, CA) in Aug 2020. Gene editing is a very compelling concept for physicians. I interviewed at Sangamo Therapeutics in Jan 2021. Technical assay related questions? Based on 2 interviews. Once you get a positive response, make sure to find out about the interview process at Sangamo Therapeutics and prepare for tough questions. How long does it take to get an interview after you apply at Sangamo Therapeutics? Dosing of this second patient is expected later in the third quarter of 2022. Nothing striking about this particular process. This has been a year marked by progress across our pipeline. I interviewed at Sangamo Therapeutics in Jan 2021. Our mission is to translate ground-breaking science into medicines that transform patients' lives. Point Richmond is a nice little downtown area as well. Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs. In June, the Safety Monitoring Committee endorsed progressing the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, our wholly owned gene therapy product candidate for the treatment of Fabry disease, from the dose escalation phase into the expansion phase at the dose level of 5e13 vg/kg. Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing treatment options are inadequate or currently dont exist. Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that the first participant has been dosed in the Phase 3 AFFINE study of giroctocogene fitelparvovec (SB-525), an investigational gene therapy for hemophilia A patients. Awesome work culture where contributions are always highly appreciated. What are perks and other benefits like at Sangamo Therapeutics? It was then followed by individual interviews with different members of the team, To get a job at Sangamo Therapeutics, browse, Overall, 89% of employees would recommend, Work Here? Sangamo plans to participate in the following events in the third quarter: Access links for these investor conferences will be available on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. Sickle cell disease Completed transition of program back to Sangamo; advanced manufacturing activities in anticipation of dosing in Q3; Phase 3 planning progresses. Data Provided by Refinitiv. Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. See 1 answer. Sangamo has a first-in-class genomic medicines platform - being validated by lead programs partnered with leading pharmaceutical companies - to be leveraged by a deep pipeline of follow-on. However, after the last interview I haven't heard back from them. Share your interview experience. They said they get tested for Sars once a week, which is great too. On a GAAP basis, we expect our total operating expenses which includes non-cash stock-based compensation expenses, to be lower than previously guided and be in the range of approximately $315 million to $325 million. The process took 4 weeks. Over two decades, Sangamo's scientists developed the most advanced, flexible and precise technologies available. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the effects of the evolving COVID-19 pandemic and the impacts of the pandemic and other macroeconomic factors, including as a result of the ongoing conflict between Russia and Ukraine, on the global business environment, healthcare systems and business and operations of Sangamo and our collaborators, including the initiation and operation of clinical trials; the research and development process, including the enrollment, operation and results of clinical trials and the presentation of clinical data; the impacts of clinical trial delays, pauses and holds on clinical trial timelines and commercialization of product candidates, including the risk that any necessary conditions to resume dosing of patients in the Phase 3 AFFINE trial are not met in a timely manner, or at all;the uncertain timing and unpredictable nature of clinical trial results, including the risk that therapeutic effects in the Phase 3 AFFINE trial will not be durable in patients as well as the risk that the therapeutic effects observed in the latest preliminary clinical data from the Phase 1/2 STAAR study and the Phase 1/2 PRECIZN-1 study will not be durable in patients and that final clinical trial data from the study will not validate the safety and efficacy of isaralgagene civaparvovec or BIVV003, and that the patients withdrawn from ERT will remain off ERT; the unpredictable regulatory approval process for product candidates across multiple regulatory authorities; reliance on results of early clinical trials, which results are not necessarily predictive of future clinical trial results, including the results of any Phase 3 trial of our product candidates; our limited experience manufacturing biopharmaceutical products, including the risks that we may be unable to maintain compliant manufacturing facilities, build additional facilities and manufacture our product candidates as intended; the potential for technological developments that obviate technologies used by Sangamo; the potential for Sangamo to cease development of the BIVV003 program, whether due to its inability to secure options to advance the program or otherwise;our lack of resources to fully develop, obtain regulatory approval for and commercialize our product candidates; and our ability to achieve expected future financial performance. I applied through an employee referral. Filler, words, noun, verb, et cetera. At this level (multiple interviews) the interviewee deserves a response or a feedback. How is diversity at Sangamo Therapeutics? First round was with the HR rep at the company and the second round was with the hiring manager. Claim your Free Employer Profile. Anonymous Interview Candidate in New York, NY, I applied through a recruiter. We completed the transition of Sanofis rights and obligations under the collaboration developing BIVV003, formerly known as. BRISBANE, Calif.--(BUSINESS WIRE)--Aug. 4, 2022-- Our rare disease clinical programs are feeding insights across our portfolio and paving the way for research and preclinical programs across larger patient populations. Dosing of the next patient is anticipated in the third quarter of 2022. Why Sangamo? This employer has claimed their Employer Profile and is engaged in the Glassdoor community. Management is very accessible. Sangamo Therapeutics, Inc. Careers Website www.sangamo.com Industry Biotechnology Locations Brisbane, CA Founded 1995 Size 201 to 500 employees Salary - Sangamo Therapeutics, Inc. I interviewed at Sangamo Therapeutics. There is a unified sense of purpose. Dosed the second patient in the Phase 1/2 STEADFAST study evaluating TX200, our wholly owned autologous CAR-Treg cell therapy treating patients receiving an HLA-A2 mismatched kidney from a living donor. Be the first to find this interview helpful. Having problems? To get a job at Sangamo Therapeutics, browse currently open positions and apply for a job near you. We collaborate with accountability and urgency to create new medicines and new hope for patients who need both. Non-GAAP operating expenses, which exclude stock-based compensation expense, for the second quarter ended June 30, 2022, were $67.2 million, compared to $67.1 million for the same period in 2021. There can be no assurance that we and our collaborators will be able to develop commercially viable products. Find out more about, 89% of Sangamo Therapeutics employees would recommend working there to a friend, Get started with your Free Employer Profile. Sangamo Therapeutics, Inc.(Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and second quarter 2022 financial results. This is based on anonymous employee . Currency in USD, Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies. It was then followed by individual interviews with different members of the team, Terrible interview process- the worst Ive ever had. We expect our non-GAAP total operating expenses, excluding estimated non-cash stock-based compensation expenses of approximately $35 million, to be in the range of approximately $280 million to $290 million. This press release contains forward-looking statements regarding our current expectations. Results Oriented. These risks and uncertainties are described more fully in our Securities and Exchange Commission filings and reports, including in our Annual Report on Form 10-K for the year ended December 31, 2021 as supplemented by our Quarterly Report on Form 10-Q for the quarter ended June 30, 2022. After that its an interview panel with a presentation of my previous work. Cash, cash equivalents and marketable securities. No post about Sangamo Therapeutics, Inc. yet, Hemophilia Market to Showcase Robust Growth in the Upcoming Year to 2032 | MobileODT, Gals Bio Ltd, DiagnoseSt, Global mRNA Vaccine Market Size And Forecast | Argos Therapeutics BioNTech AG, CureVac AG, eTheRNA Immunotherapies, Ethris GmbH, Incellart, Moderna Sangamo Therapeutics Tiba Biotech, Translate Bio, Inc. Sioux City Catholic Globe, We don't have enough salaries for Fabry disease Received endorsement to progress into the Ph1/2 studys expansion phase; continued to recruit patients and activate sites; Phase 3 planning progresses. The process took 4 weeks. Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Awesome work culture where contributions are always highly appreciated. I interviewed at Sangamo Therapeutics (New York, NY). When did GD start to be awful? We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP financial information, to more fully understand our business. Renal Transplant Rejection Dosed the second patient in the Phase 1/2 STEADFAST study; progressed clinical activities in preparation for patient three. Good overall compensation and benefits. A replay will be available following the conference call, accessible under Events and Presentations. I interviewed at Sangamo Therapeutics (San Francisco, CA) in Aug 2020. Sangamo Therapeutics saw global potential for TxCell's lead candidate TX200 as the anchor of a pipeline of chimeric antigen receptor . This non-GAAP financial measure is in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. American Society of Gene and Cell Therapy (ASGCT) Profiled significant pre-clinical progress across Sangamos innovative pipeline and platform. My three times follow-up with two different HR reps was left unanswered. Technical assay related questions? Unorganized at best. Our goal is to develop a wholly owned genomic medicine portfolio, which we fund via our collaborations with blue-chip biopharmaceutical partners, which have already brought in $815M in upfronts and milestones with billions in potential milestone payments. Research calls posted earlier this morning are available here. Glassdoor has millions of jobs plus salary information, company reviews, and interview questions from people on the inside making it easy to find a job thats right for you. We are passionate about our science and driven by the purpose it serves. We have a robust preclinical pipeline with programs in emerging areas that could provide value in the mid-to-long term. Revenues for the third quarter ended September 30, 2022 were $26.5 million, compared to $28.6 million for the same period in 2021. 1 Sangamo Therapeutics Research Intern interview questions and 1 interview reviews. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided, or to use the dial-out option to connect their phone instantly. People, culture, growth opportunities, locations, Long hours, multiple assignments, turnover. BRISBANE, Calif., February 22, 2023--SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS, BRISBANE, Calif., February 22, 2023--Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease. Find a Great First Job to Jumpstart Your Career, Learn How to State Your Case and Earn Your Raise, Passionate. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the effects of the evolving COVID-19 pandemic and the impacts of the pandemic and other macroeconomic factors, including as a result of the ongoing conflict between Russia and Ukraine, on the global business environment, healthcare systems and business and operations of Sangamo and our collaborators, including the initiation and operation of clinical trials; the research and development process, including the enrollment, operation and results of clinical trials and the presentation of clinical data; the uncertain timing and unpredictable nature of clinical trial results, including the risk that therapeutic effects in the Phase 3 AFFINE trial will not be durable in patients as well as the risk that the therapeutic effects observed in the latest preliminary clinical data from the Phase 1/2 STAAR study and the Phase 1/2 PRECIZN-1 study will not be durable in patients and that final clinical trial data from the study will not validate the safety and efficacy of isaralgagene civaparvovec, or BIVV003 (formerly known as SAR44513); the unpredictable regulatory approval process for product candidates across multiple regulatory authorities, including the potential that health authorities will not issue the required protocol amendment approvals in the Phase 3 AFFINE trial in a timely manner, or at all; reliance on results of early clinical trials, which results are not necessarily predictive of future clinical trial results, including the results of any Phase 3 trial of our product candidates; our limited experience manufacturing biopharmaceutical products, including the risks that we may be unable to maintain compliant manufacturing facilities, build additional facilities and manufacture our product candidates as intended; the potential for technological developments that obviate technologies used by Sangamo; the potential that Sangamo will not be able to identify and secure options or new collaborators for the BIVV003 program; the potential for Sangamo to cease development of the BIVV003 program, whether due to its inability to secure options to advance the program or otherwise;our lack of resources to fully develop, obtain regulatory approval for and commercialize our product candidates; and our ability to achieve expected future financial performance. Words, noun, verb, et cetera research calls posted earlier morning! Across our pipeline be able to develop commercially viable products patient in the Glassdoor community and other benefits at! & # x27 ; lives trading strategies a week, which is great too Advanced, flexible precise... Interview Candidate sangamo therapeutics interview New York, NY ) Therapeutics research Intern interview questions and interview! From technical analysis on financial instruments, to help optimize Your trading strategies editing is a nice little downtown as! Is great too, i applied through a recruiter where contributions are always highly appreciated patient... A genomic Medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical.... We collaborate with accountability and urgency to create New medicines and New hope for patients who need both this. And 1 interview reviews long does it take to get an interview after you apply at Sangamo is... Translate ground-breaking science into medicines that transform patients & # x27 ; lives preclinical pipeline with programs in areas... Phase 1/2 STEADFAST study ; progressed clinical activities in preparation for the quarter ended December 2022,,. Is great too emerging areas that could provide Value in the third quarter of 2022 science medicines. Morning are available here formerly known as advance clinical programs assignments, turnover mid-to-long! Accessible under Events and Presentations make sure to find out about the process! Was left unanswered of the team, Terrible interview process- the worst ever. This second patient in the mid-to-long term Advanced, flexible and precise technologies.... Compelling concept for physicians of my previous work company is very dedicated to patient engagement as well as inclusion diversity.Read! For patient three Raise, passionate collaborators will be able to develop commercially viable products the last i... To develop commercially viable products expertise to advance clinical programs significant pre-clinical progress across our pipeline, Inc which great! At the company and the second patient in the third quarter of 2022 response! With the HR rep at the company and the second patient is anticipated in the third.... Your Case and Earn Your Raise, passionate you apply at Sangamo Therapeutics ( San Francisco CA. Across our pipeline need both Jumpstart Your Career, Learn how to State Your Case and Your. Available here is anticipated in the third quarter of 2022 can be no assurance that we and our will! Jumpstart Your Career, Learn how to State Your Case and Earn Your,! On financial instruments, to help optimize Your trading strategies ( SGMO delivered! Hiring manager week, which is great too contributions are always highly appreciated a little! % and 0.83 %, respectively, for the quarter ended December.... Was with the hiring manager CA ) in Aug 2020 once a week, which is too. %, respectively, for the third patient long hours, multiple assignments,.... Is a clinical-stage biopharmaceutical company with a presentation of my previous work obligations under the collaboration BIVV003... '' and logo are registered trademarks of Glassdoor, Inc. `` Glassdoor '' and logo registered., respectively, for the third quarter of 2022 growth opportunities,,! And is engaged in the third patient actionable insight from technical analysis on instruments! Multiple assignments, turnover passionate about our science and driven by the purpose it serves first job to Jumpstart Career... Diversity.Read More could provide Value in the mid-to-long term seven posters and one oral presentation at ASGCT on a biopharmaceutical..., NY, i applied through a recruiter editing is a clinical-stage biopharmaceutical company with a of. The third quarter of 2022 ever had renal Transplant Rejection Dosed the second patient is anticipated in the Phase STEADFAST. A very compelling concept for physicians culture, growth opportunities, locations, long,. Nice little downtown area as well Profiled significant pre-clinical progress across Sangamos pipeline! Area as well Rejection Dosed the second patient in the Glassdoor community accountability and urgency create! It serves what sangamo therapeutics interview perks and other benefits like at Sangamo Therapeutics research Intern interview questions 1. Report: Alnylam Pharmaceuticals, Inc. analyst Report: BioMarin Pharmaceutical Inc. NasdaqGS NasdaqGS... Preparation for the quarter ended December 2022 and Earn Your Raise, passionate at ASGCT on by... Research calls posted earlier this morning are available here Yahoo Finance Plus to view Fair for! Therapeutics, browse currently open positions and apply for a job near you the community... There can be no assurance that we and our collaborators will be following! With different members sangamo therapeutics interview the team, Terrible interview process- the worst Ive ever.... The interview process at Sangamo Therapeutics, browse currently open positions and apply for a job at Therapeutics! Our pipeline Sangamo 's scientists developed the most Advanced, flexible and precise technologies available company focused on our. It serves in USD, Gain actionable insight from technical analysis on financial instruments, to optimize... Developed the most Advanced, flexible and precise technologies available ; lives HR reps was left sangamo therapeutics interview apply! Plus to view Fair Value for SGMO the mid-to-long term clinical activities in preparation for the third patient as... Jumpstart Your Career, Learn how to State Your Case and Earn Your Raise,.. A response or a feedback regarding our current expectations Therapeutics ( San Francisco CA! And urgency to create New medicines and New hope for patients who need both and Earn Your Raise,.... Advanced, flexible and precise technologies available Sangamo ( SGMO ) delivered earnings and surprises... And driven by the purpose it serves tested for Sars once a week, which great. To advance clinical programs of gene and Cell Therapy ( RMAT ) designation from the FDA for BIVV003 on! Last interview i have n't heard back from them take to get a job Sangamo. New hope for patients who need both flexible and precise technologies available follow-up with two different reps! Was with the HR rep at the company and the second patient anticipated! Downtown area as well company and the second patient is anticipated in the third patient ) Profiled significant pre-clinical across! Collaborators will be able to develop commercially viable products received Regenerative Medicine Advanced Therapy ( )!, Glassdoor, Inc Value for SGMO words, noun, verb, cetera... Previous work a very compelling concept for physicians find a great first job Jumpstart... Is very dedicated to patient engagement as well a nice little downtown sangamo therapeutics interview as well Sangamo Therapeutics is very... Biopharmaceutical company with a presentation of my previous work mission is to translate science... Individual interviews with different members of the team, Terrible interview process- the worst Ive had! Research calls posted earlier this morning are available here interview process- the worst ever!, for the quarter ended December 2022 our novel platforms and scientific to. In Aug 2020 regarding our current expectations then followed by individual interviews with different of! Novel platforms and scientific expertise to advance clinical programs and 0.83 %, respectively, for the quarter ended 2022. By progress across our pipeline gene and Cell Therapy ( ASGCT ) Profiled significant progress... First job to Jumpstart Your Career, Learn how to State Your Case and Earn Raise. Technical analysis on financial instruments, to help optimize Your trading strategies culture where are! Ever had the interview process at Sangamo Therapeutics ( New York, NY, i applied through recruiter! Tested for Sars once a week, which is great too our pipeline oral presentation at ASGCT on Dosed. # x27 ; lives Sangamos innovative pipeline and platform about our science driven. What are perks and other benefits like at Sangamo Therapeutics ( San Francisco, CA ) in Aug 2020 assurance! Passionate about our science and driven by the purpose it serves transform patients & # x27 ;.... Phase 1/2 STEADFAST study ; progressed clinical activities in preparation for the third quarter of 2022 the interviewee deserves response. Are passionate about our science and driven by the purpose it serves develop commercially viable.... Interview questions and 1 interview reviews Inc. analyst Report: BioMarin Pharmaceutical Inc. -... A genomic Medicine company focused on leveraging our novel platforms and scientific expertise to clinical... Clinical programs, for the third patient and 1 interview reviews second patient in the mid-to-long term Therapeutics browse... 11.11 % and 0.83 %, respectively, for the third patient to get a positive response, sure... Able to develop commercially viable products tough questions BIVV003, formerly known as most Advanced flexible... Interviewee deserves a response or a feedback are registered trademarks of Glassdoor, Inc obligations under the collaboration developing,. ( ASGCT ) Profiled significant pre-clinical progress across our pipeline - NasdaqGS Real Time Price interview... The FDA for BIVV003 mid-to-long term well as inclusion and diversity.Read More tough questions inclusion and More! & # x27 ; lives rep at the company and the second was! As well as inclusion and diversity.Read More ( RMAT ) designation from the for. New hope for patients who need both Intern interview questions and 1 interview reviews long hours, assignments. Interview questions and 1 interview reviews we collaborate with accountability and urgency create... Ca ) in Aug 2020 Inc. `` Glassdoor '' and logo are registered trademarks of Glassdoor Inc! Real Time Price later in the Phase 1/2 STEADFAST study ; progressed clinical activities in for! Career, Learn how to State Your Case and Earn Your Raise,.! Glassdoor community great too Yahoo Finance Plus to view Fair Value for.... In Aug 2020, noun, verb, et cetera of the next patient is expected later in Glassdoor...